Novartis India Share Price
2046.80-35.40 (-1.70%)
+105.62% past 1 Year
Corporate filings & documents
Announcements
Corrigendum to the Notice of 78th Annual General Meeting dated August 27 2026
2 days agoCorrigendum to the Notice of 78th Annual General Meeting dated August 27 2026
2 days agoTranscript of the Analysts / Institutional Investors Call held on September 11 2026.
5 days agoTranscript of the Analysts / Institutional Investors Call held on September 11 2026.
5 days agoIntimation of the Audio Recording of the Investor / Analyst Call held on Friday September 11 2026.
1 week agoIntimation of the Audio Recording of the Investor / Analyst Call held on Friday September 11 2026.
1 week agoWith reference to the intimation of the Investor / Analyst Call dated September 08 2026 please find attached herewith the Investor Presentation in relation to the same.
1 week agoWith reference to the intimation of the Investor / Analyst Call dated September 08 2026 please find attached herewith the Investor Presentation in relation to the same.
1 week agoIntimation pursuant to Regulation 36(1)(b) of the SEBI LODR Regulations to non-email shareholders regarding the Weblink and Annual Report for FY 2025-26 by the way of physical dispatch of letters.
1 week agoIntimation pursuant to Regulation 36(1)(b) of the SEBI LODR Regulations to non-email shareholders regarding the Weblink and Annual Report for FY 2025-26 by the way of physical dispatch of letters.
1 week agoIntimation regarding the Investor / Analyst Call scheduled to be held on Friday September 11 2026 04:00 PM IST onwards through Physical and Virtual Mode.
1 week agoIntimation regarding the Investor / Analyst Call scheduled to be held on Friday September 11 2026 04:00 PM IST onwards through Physical and Virtual Mode.
1 week agoIntimation under Reg 30 of SEBI LODR regarding entering into Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited for its retina portfolio comprising the products Accentrix (ranibizumab) and Pagenax (brolucizumab).
1 week agoIntimation under Reg 30 of SEBI LODR regarding entering into Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited for its retina portfolio comprising the products Accentrix (ranibizumab) and Pagenax (brolucizumab).
1 week agoIntimation regarding the acquisition of trademarks "Minipress" and "Minipres" registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products Inc. USA and the same is approved by the Board of Directors at their meeting held today i.e. September 07 2026.
1 week agoIntimation regarding the acquisition of trademarks "Minipress" and "Minipres" registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products Inc. USA and the same is approved by the Board of Directors at their meeting held today i.e. September 07 2026.
1 week agoNewspaper Publication made on September 03 2026 in Financial Express and Navshakti for the Intimation sent to the shareholders on September 02 2026 regarding the Notice of the 78th Annual General Meeting scheduled to be held on September 24 2026.
2 weeks agoNewspaper Publication made on September 03 2026 in Financial Express and Navshakti for the Intimation sent to the shareholders on September 02 2026 regarding the Notice of the 78th Annual General Meeting scheduled to be held on September 24 2026.
2 weeks agoAnnual Report of Novartis India Limited for FY 2025-26
2 weeks agoAnnual Report of Novartis India Limited for FY 2025-26
2 weeks agoNotice of the 78th Annual General Meeting of Novartis India Limited to be held on Thursday September 24 2026 through Video Conferencing (VC) / Other Audio Visual Means (OAVM)
2 weeks agoNotice of the 78th Annual General Meeting of Novartis India Limited to be held on Thursday September 24 2026 through Video Conferencing (VC) / Other Audio Visual Means (OAVM)
2 weeks agoBRSR Report of Novartis India Limited for FY 2025-26
2 weeks agoBRSR Report of Novartis India Limited for FY 2025-26
2 weeks agoThe Intimation is submitted with BSE regarding the information provided to the Members of the Company for the 78th Annual General Meeting through Newspaper Advertisement
3 weeks agoThe Intimation is submitted with BSE regarding the information provided to the Members of the Company for the 78th Annual General Meeting through Newspaper Advertisement
3 weeks agoOutcome of the meeting of the Board of Directors of the Company held on August 17 2026
1 month agoOutcome of the meeting of the Board of Directors of the Company held on August 17 2026
1 month agoIntimation of the outcome of the Board Meeting held today i.e. August 07 2026
1 month agoIntimation of the outcome of the Board Meeting held today i.e. August 07 2026
1 month agoDisclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 for the Press Release.
1 month agoDisclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 for the Press Release.
1 month agoOutcome of the 247th meeting of the Board of Directors held today i.e Wednesday July 29 2026.
1 month agoOutcome of the 247th meeting of the Board of Directors held today i.e Wednesday July 29 2026.
1 month agoOutcome of the 246th Board Meeting of the Board of Directors of Novartis India Limited held today i.e Wednesday July 29 2026.
1 month agoOutcome of the 246th Board Meeting of the Board of Directors of Novartis India Limited held today i.e Wednesday July 29 2026.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e Wednesday July 29 2026 took note of the Resignation of Mr. Christopher David Snook as the chairperson of the company.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e Wednesday July 29 2026 took note of the Resignation of Mr. Christopher David Snook as the chairperson of the company.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e Wednesday July 29 2026 took note of the Resignation of the Directors of the company.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e Wednesday July 29 2026 took note of the Resignation of the Directors of the company.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e Wednesday July 26 2026 took note of resignation of Ms. Shilpa Joshi as the Chief Financial Officer of the Company pursuant to the Company Covenant and Warranty Deed.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e Wednesday July 26 2026 took note of resignation of Ms. Shilpa Joshi as the Chief Financial Officer of the Company pursuant to the Company Covenant and Warranty Deed.
1 month agoThe Board of Directors of Novartis India Limited ("the Company) in its meeting today July 29 2026 approved the Change in Control of the Company.
1 month agoThe Board of Directors of Novartis India Limited ("the Company) in its meeting today July 29 2026 approved the Change in Control of the Company.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its Meeting held today July 29 2026 approved the Cessation of the exisiting Directors.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") at its Meeting held today July 29 2026 approved the Cessation of the exisiting Directors.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") held today i.e Wednesday July 29 2026 approved the Appointment and Resignation of Directors.
1 month agoThe Board of Directors of Novartis India Limited ("the Company") held today i.e Wednesday July 29 2026 approved the Appointment and Resignation of Directors.
1 month agoDisclosure in terms of Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ("SAST") Regulations 2015.
1 month agoDisclosure in terms of Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ("SAST") Regulations 2015.
1 month agoAnnual reports
Concalls & investor presentations
May 2026
ConcallPresentation